首页> 外文期刊>Canadian Association of Radiologists journal >Impact of Levovist ultrasonographic contrast agent on the diagnosis and management of hypertensive patients with suspected renal artery stenosis: a Canadian multicentre pilot study.
【24h】

Impact of Levovist ultrasonographic contrast agent on the diagnosis and management of hypertensive patients with suspected renal artery stenosis: a Canadian multicentre pilot study.

机译:Levovist超声造影剂对疑似肾动脉狭窄的高血压患者的诊断和管理的影响:一项加拿大多中心先导研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To compare the diagnoses obtained with unenhanced ultrasonography (US), contrast-enhanced US and captopril-enhanced renal scintigraphy and to determine whether use of a contrast agent improves ability to assess the renal arteries with duplex Doppler US. SUBJECTS AND METHODS: The study was an open-label controlled trial involving 78 patients with hypertension suspected to have a renovascular cause. The patients underwent captopril-enhanced scintigraphy or routine unenhanced US (the usual diagnostic methods at the centres where the study was conducted) and contrast-enhanced US (with Levovist, Berlex Canada, Lachine, Que.). The patients were followed for 3 months after the diagnostic tests were performed. RESULTS: Enhanced US yielded a diagnosis for a significantly greater proportion of patients than did unenhanced US (77 [99%] v. 64 [82%] of 78 patients; p = 0.002) or captopril-enhanced scintigraphy (71 [99%] v. 58 [81%] of 72 patients; p = 0.002). Diagnosis was possible with both enhanced and unenhanced duplex Doppler US in only 64 (82%) of the 78 patients, and the diagnosis was the same with both methods for 63 (98%) of these 64 patients. In contrast, diagnosis was possible for only 58 (81%) of the 72 patients who underwent both enhanced US and captopril-enhanced scintigraphy; the same diagnosis was reported in 53 (91%) of these 58 cases. During follow-up, 11 patients (21 kidneys) underwent angiography. Significant stenosis was detected in 6 (55%) of the patients (8 [38%] of the kidneys). Both the enhanced and unenhanced US results agreed more often with angiography than did captopril-enhanced scintigraphy (9 [82%] v. 8 [73%] of the 11 patients). The proportion of patients in whom the left and right renal artery could be assessed by duplex Doppler US increased significantly (by 58% and 43%, respectively) with use of the contrast agent. CONCLUSION: Enhanced US had a higher rate of successful diagnosis than unenhanced US and captopril-enhanced renal scintigraphy. Enhanced US might therefore be suitable as a screening method for hypertensive patients with suspected renal artery stenosis.
机译:目的:比较超声造影,超声造影和卡托普利超声造影所获得的诊断结果,并确定使用造影剂是否可以改善双相多普勒超声评估肾动脉的能力。受试者与方法:该研究是一项开放标签对照试验,涉及78位怀疑有肾血管病原因的高血压患者。患者接受了卡托普利增强的闪烁显像术或常规的未增强的美国超声(在研究进行的中心采用常规诊断方法)和对比增强的美国超声(与Levovist,加拿大Berlex,Lachine,Que)。在进行诊断测试后,对患者进行了3个月的随访。结果:增强型US诊断的患者比例明显高于未增强US(78名患者中的77 [99%]比64 [82%]; p = 0.002)或卡托普利增强闪烁显像(71 [99%]) v。72位患者中的58位[81%]; p = 0.002)。在78例患者中,只有64例(82%)可以使用增强型和未增强双相多普勒超声进行诊断,这64例患者中的63例(98%)的诊断方法相同。相比之下,接受超声和卡托普利增强闪烁显像的72例患者中,只有58例(81%)可以诊断。在这58例病例中,有53例(91%)报告了相同的诊断。在随访期间,对11例患者(21个肾脏)进行了血管造影。在6名患者(55%)(8 [38%]肾脏)中发现了严重的狭窄。与卡托普利增强闪烁显像术相比,增强的和未增强的美国结果在血管造影上的同意率更高(11例患者中9例[82%]对8例[73%])。使用造影剂可以通过双工多普勒超声评估左肾动脉和右肾动脉的患者比例显着增加(分别增加了58%和43%)。结论:增强型US的成功诊断率高于未增强的US和卡托普利增强的肾闪烁显像。因此,增强型超声检查可能适合作为可疑肾动脉狭窄的高血压患者的筛查方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号